PDGFRβ-specific antibodies
US7740850B2 · kind B2 · utility
20Cited by
9References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 17, 2008 |
| Grant date | Jun 22, 2010 |
| Priority date | — |
| Expiry date | May 13, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is directed to novel PDGFRβ-specific antagonists. The antagonists include antibodies, which can be bispecific. The antibodies are used to reduce or inhibit tumor growth and or to treat an angiogenic disease. The invention also includes combinations of PDGFRβ-specific antagonists with VEGFR antagonists for such treatments. The antagonists can further be administered in combination with other anti-angiogenic or anti-neoplastic drugs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.